Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome

Leukemia and Lymphoma

Volumn 54, Issue 1, 2013, Pages 69-75

  Prince, H Miles ^a   Martin, Ann G ^b   Olsen, Elise A ^c   Fivenson, David P ^d   Duvic, Madeleine ^e  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d HENRY FORD HOSPITAL   (United States)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

Antigens; CD25; Cutaneous T cell lymphoma; Denileukin diftitox; Mycosis fungoides; S zary syndrome

Indexed keywords

DENILEUKIN DIFTITOX; INTERLEUKIN 2 RECEPTOR ALPHA;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; ASTHENIA; CAPILLARY LEAK SYNDROME; CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; FAINTNESS; FATIGUE; FEMALE; FEVER; HUMAN; HYPERSENSITIVITY; IMMUNOHISTOCHEMISTRY; LUNG EMBOLISM; LYMPHOCYTOPENIA; MALE; MULTICENTER STUDY; MYCOSIS FUNGOIDES; NAUSEA; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RIGOR; SEZARY SYNDROME; SIDE EFFECT; SKIN BIOPSY; TACHYCARDIA; THORAX PAIN; TREATMENT FAILURE; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DIPHTHERIA TOXIN; FEMALE; HUMANS; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; NEOPLASM STAGING; RECOMBINANT FUSION PROTEINS; SEZARY SYNDROME; TREATMENT OUTCOME;

EID: 84870864812     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.706286     Document Type: Article

References (18)

1. Kashani-Sabet M, McMillan A, Zackheim HS. A modifi ed staging classifi cation for cutaneous T-cell lymphoma. J Am Acad Dermatol 2001 ; 45: 700-706. (Pubitemid 33032566)
2. Willemze R, Jaff e ES, Burg G, et al. WHO-EORTC classifi cation for cutaneous lymphomas. Blood 2005; 105: 3768- 3785. (Pubitemid 40656118)
3. N ichols J, F oss F, K uzel T M, et al. I nterleukin-2 fusion protein: An investigational therapy for interleukin-2 receptor expressing malignancies. Eur J Cancer 1997; 33(Suppl. 1): S34- S36.
4. T alpur R, J ones D M, A lencar A J, et al. C D25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. J Invest Dermatol 2006; 126: 575- 583. (Pubitemid 43255644)
5. Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001 ; 19: 376-388. (Pubitemid 32112849)
6. Re GG, Waters C, Poisson L, et al. Interleukin 2 (IL-2) receptor expression and sensitivity to diphteria fusion toxin DAB389IL-2 in cultured hematopoietic cells. Cancer Res 1996 ; 56: 2590-2595.
7. Foss F. Overview of cutaneous T-cell lymphoma: Prognostic factors and novel therapeutic approaches. Leuk Lymphoma 2003; 44(Suppl. 3): S55- S61. (Pubitemid 38196064)
8. Ontak [package insert]. Woodcliff Lake, NJ: Eisai Medical Research Inc., 2010.
9. Prince HM, Duvic M, Martin A, et al. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol 2010 ; 28: 1870-1877.
10. Jones D, Ibrahim S, Patel K, et al. Degree of CD25 expression in T-cell lymphoma is dependent on tissue site: Implications for targeted therapy. Clin Cancer Res 2004; 10: 5587- 5594. (Pubitemid 39100500)
11. Talpur R, Apisarnthanarax N, Ward S, et al. Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK). Leuk Lymphoma 2002; 43: 121- 126. (Pubitemid 34223979)
12. Bunn PA Jr, Lamberg SI. Report of the Committee on Staging and Classifi cation of Cutaneous T-Cell Lymphomas. Cancer Treat Rep 1979 ; 63: 725-728. (Pubitemid 9217604)
13. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classifi cation of mycosis fungoides and Sezary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007 ; 110: 1713-1722. (Pubitemid 47443880)
14. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007 ; 25: 3109-3115. (Pubitemid 47218059)
15. Prince HM, Duvic M, Martin A, et al. Incidence of spontaneous remission in patients with CD25-positive mycosis fungoides/Sezary syndrome receiving placebo. J Am Acad Dermatol 2012; 67: 867- 875.
16. Duvic M, Hymes K, Heald P, et al. Bexarotene is eff ective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational phase II-III trial results. J Clin Oncol 2001 ; 19: 2456-2471. (Pubitemid 32391217)
17. Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010 ; 28: 4485-4491.
18. Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009 ; 27: 5410-5417.